# Alternative Dosing for CRLX101(NLG207) Alone, With Avastin and With mFOLFOX6 in Advanced Solid Tumors

> **NCT02648711** · PHASE1 · TERMINATED · sponsor: **NewLink Genetics Corporation** · enrollment: 41 (actual)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** CRLX101
- **DRUG:** Bevacizumab
- **DRUG:** mFOLFOX6

## Key facts

- **NCT ID:** NCT02648711
- **Lead sponsor:** NewLink Genetics Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-10
- **Primary completion:** 2017-10-17
- **Final completion:** 2018-05-07
- **Target enrollment:** 41 (ACTUAL)
- **Why stopped:** Company decision
- **Last updated:** 2020-05-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02648711

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02648711, "Alternative Dosing for CRLX101(NLG207) Alone, With Avastin and With mFOLFOX6 in Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02648711. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*